These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses. Avivi I; Luttwak E; Saiag E; Halperin T; Haberman S; Sarig A; Levi S; Aharon A; Herishanu Y; Perry C Br J Haematol; 2022 Mar; 196(6):1329-1333. PubMed ID: 35075635 [TBL] [Abstract][Full Text] [Related]
8. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093 [TBL] [Abstract][Full Text] [Related]
9. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults. Romero-Olmedo AJ; Schulz AR; Hochstätter S; Das Gupta D; Virta I; Hirseland H; Staudenraus D; Camara B; Münch C; Hefter V; Sapre S; Krähling V; Müller-Kräuter H; Widera M; Mei HE; Keller C; Lohoff M Nat Microbiol; 2022 Feb; 7(2):195-199. PubMed ID: 35013593 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine. Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875 [TBL] [Abstract][Full Text] [Related]
11. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. Re D; Seitz-Polski B; Brglez V; Carles M; Graça D; Benzaken S; Liguori S; Zahreddine K; Delforge M; Bailly-Maitre B; Verrière B; Chamorey E; Barrière J Nat Commun; 2022 Feb; 13(1):864. PubMed ID: 35165284 [TBL] [Abstract][Full Text] [Related]
12. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. Cohen D; Hazut Krauthammer S; Cohen YC; Perry C; Avivi I; Herishanu Y; Even-Sapir E Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3540-3549. PubMed ID: 33966088 [TBL] [Abstract][Full Text] [Related]
13. Decline of immune humoral response after BNT162b2 vaccine. Ferri S; Polidoro A; Ciacciarelli M; Ceratti U; Congedo V; Mele M; Coluzzi G; Spagnoli A; Iuliano L J Infect; 2022 Apr; 84(4):e34-e35. PubMed ID: 35183610 [No Abstract] [Full Text] [Related]